Etanercept’s New Autoinjection System; Plus FDA Approves Ixekizumab for Active PsA

In both studies, the primary efficacy endpoint was the proportion of patients achieving an ACR20 response at Week 24. Ixekizumab-treated patients achieved significant improvement in joint symptoms compared with placebo-treated patients. At Week 24 in the SPIRIT-P1 study, 58% of ixekizumab-treated patients compared with 30% of placebo-treated patients achieved ACR20. And in the SPRIT-P2 study, 53% of ixekizumab-treated patients compared with 20% of placebo-treated patients achieved ACR20.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

1. Amgen Inc. Amgen launches the Enbril Mini single-dose, prefilled cartridge with AutoTouch reusable autoinjector that is ergonomically designed for patients. 2017 Nov. 17.
2. Eli Lilly and Company. Lilly’s Taltz (ixekizumab) receives U.S. FDA approval for the treatment of active psoriatic arthritis. 2017 Dec 1.